The ischemia-induced death of cardiomyocytes results in scar formation and reduced contractility of the ventricle. Several preclinical and clinical studies have supported the notion that cell therapy may be used for cardiac regeneration. Most attempts for cardiomyoplasty have considered the bone marrow as the source of the “repair stem cell(s),” assuming that the hematopoietic stem cell can do the work. However, bone marrow is also the residence of other progenitor cells, including mesenchymal stem cells (MSCs). Since 1995 it has been known that under in vitro conditions, MSCs differentiate into cells exhibiting features of cardiomyocytes. This pioneer work was followed by many preclinical studies that revealed that ex vivo expanded, bone marrow–derived MSCs may represent another option for cardiac regeneration. In this work, we review evidence and new prospects that support the use of MSCs in cardiomyoplasty.
UrbanekK, TorellaD, SheikhF, De AngelisA, NurzynskaD, SilvestriF, BeltramiCA, BussaniR, BeltramiAP, QuainiF, BolliR, LeriA, KajsturaJ, AnversaP. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A102: 8692–8697, 2005.
4.
WarejckaDJ, HarveyR, TaylorBJ, YoungHE, LucasPA. A population of cells isolated from rat heart capable of differentiating into several mesodermal phenotypes. J Surg Res62: 233–242, 1996.
BelA, MessasE, AgbulutO, RichardP, SamuelJL, BrunevalP, HagegeAA, MenascheP. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation108: 247–252, 2003.
NeuhuberB, GalloG, HowardL, KosturaL, MackayA, FischerI. Reevaluation of in vitro differentiation protocols for bone marrow stromal cells: disruption of actin cytoskeleton induces rapid morphological changes and mimics neuronal phenotype. J Neurosci Res77: 192–204, 2004.
18.
FernandezM, SimonV, HerreraG, CaoC, Del FaveroH, MinguellJJ. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Transplant20: 265–271, 1997.
19.
EricesA, CongetP, MinguellJJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol109: 235–242, 2000.
20.
CongetPA, AllersC, MinguellJJ. Identification of a discrete population of human bone-marrow derived mesenchymal cells exhibiting properties of uncommitted progenitors. J Hematother Stem Cell Res10: 749–758, 2001.
21.
CongetPA, MinguellJJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol28: 382–390, 2000.
22.
PartridgeK, YangX, ClarkeNM, OkuboY, BesshoK, SebaldW, HowdelSM, ShakesheffKM, OreffoRO. Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. Biochem Biophys Res Commun292: 144–152, 2002.
23.
HorwitzEM, ProckopDJ, FitzpatrickLA, KooWW, GordonPL, NeelM, SussmanM, OrchardP, MarxJC, PyeritzRE, BrennerMK. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med5: 309–313, 1999.
24.
BarryFP, MurphyJM. Mesenchymal stem cells: clinical application and biological properties. Int J Biochem Cell Biol36: 568–584, 2004.
25.
PiersmaAH, PloemacherRE, BrockbankKG. Transplantation of bone marrow fibroblastoid stromal cells in mice via the intravenous route. Br J Haematol54: 285–290, 1983.
26.
PereiraRF, HalfordKW, O'haraMD, LeeperDB, SokolovBP, PollardMD, BagasraO, ProckopDJ. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A92: 4857–4861, 1995.
27.
DevineSM, CobbsC, JenningsM, BartholomewA, HoffmanR. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into non human primates. Blood101: 2999–3001, 2003.
28.
AllersC, SierraltaWD, NeubauerS, RiveraF, MinguellJJ, CongetPA. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation78: 503–508, 2004.
29.
WakitaniS, SaitoT, CaplanA. Myogeneic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve18: 1417–1426, 1995.
30.
MakinoS, FukudaK, MiyoshiS, KonishiF, KodamaH, PanJ, SanoM, TakahashiT, HoriS, AbeH, HataJ, UmezawaA, OgawaS. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest103: 697–705, 1999.
31.
BittiraB, KuangJQ, Al-KhaldiA, Shum-TimD, ChiuRC. In vitro preprogramming of marrow stromal cells for myocardial regeneration. Ann Thorac Surg74: 1154–1159, 2002.
32.
MinJY, SullivanMF, YangY, ZhangJP, ConversoKL, MorganJP, XiaoYF. Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. Ann Thorac Surg74: 1568–1575, 2002.
33.
TomaC, PittengerMF, CahillKS, ByrneBJ, KesslerPD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation105: 93–98, 2002.
34.
ChengF, ZouP, YangH, YuZ, ZhongZ. Induced differentiation of human cord blood mesenchymal stem/progenitor cells into cardiomyocyte-like cells in vitro. J Huazhong Univ Sci Technolog Med Sci23: 154–157, 2003.
35.
EricesAA, AllersCI, CongetPA, RojasCV, MinguellJJ. Human cord blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion. Cell Transplant12: 555–561, 2003.
36.
FukudaK. Application of mesenchymal stem cells for the regeneration of cardiomyocyte and its use for cell transplantation therapy. Hum Cell16: 83–94, 2003.
37.
FukuharaS, TomitaS, YamashiroS, MorisakiT, YutaniC, KitamuraS, NakataniT. Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal cells to go into cardiac lineage in vitro. J Thorac Cardiovasc Surg125: 1470–1480, 2003.
38.
MangiAA, NoiseuxN, KongD, HeH, RezvaniM, IngwallJS, DzauVJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med9: 1195–1201, 2003.
NagayaN, FujiiT, IwaseT, OhgushiH, ItohT, UematsuM, YamagishiM, MoriH, KangawaK, KitamuraS. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol287: H2670–H2676, 2004.
42.
PotapovaI, PlotnikovA, LuZ, DaniloPJr, ValiunasV, QuJ, DoroninS, ZuckermanJ, ShlapakovaIN, GaoJ, PanZ, HerronAJ, RobinsonRB, BrinkPR, RosenMR, CohenIS. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res94: 952–959, 2004.
43.
ShimWS, JiangS, WongP, TanJ, ChuaYL, TanYS, SinYK, LimCH, ChuaT, TehM, LiuTC, SimE. Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun324: 481–488, 2004.
44.
VanelliP, BeltramiS, CesanaE, CiceroD, ZazaA, RossiE, CicirataF, AntonaC, ClivioA. Cardiac precursors in human bone marrow and cord blood: in vitro cell cardiogenesis. Ital Heart J5: 384–388, 2004.
45.
XuW, ZhangX, QianH, ZhuW, SunX, HuJ, ZhouH, ChenY. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype, in vitro. Exp Biol Med229: 623–631, 2004.
46.
HirataY, SataM, MotomuraN, TakanashiM, SuematsuY, OnoM, TakamotoS. Human umbilical cord blood cells improve cardiac function after myocardial infarction. Biochem Biophys Res Commun327: 609–614, 2005.
47.
ZhaoP, IseH, HongoM, OtaM, KonishiI, NikaidoT. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation79: 528–535, 2005.
48.
ValiunasV, DoroninS, ValiunieneL, PotapovaI, ZuckermanJ, WalcottB, RobinsonRB, RosenMR, BrinkPR, CohenIS. Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J Physiol555: 617–626, 2004.
49.
BirdSD, DoevendansPA, van RooijenMA, Brutel de la RiviereA, HassinkRJ, PassierR, MummeryCL. The human adult cardiomyocyte phenotype. Cardiovasc Res58: 423–434, 2003.
50.
KatwaLC. Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo. Am J Physiol Heart Circ Physiol285: H1132–H1139, 2003.
51.
RafiiS, AvecillaS, ShmelkovS, ShidoK, TejadaR, MooreMA, HeissigB, HattoriK. Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Ann N Y Acad Sci996: 49–60, 2003.
52.
HellstromM, KalenM, LindahlP, AbramssonA, BetsholtzC. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development126: 3047–3055, 1999.
53.
GojoS, GojoN, TakedaY, MoriT, AbeH, KyoS, HataJ, UmezawaA. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res288: 51–59, 2003.
54.
DavaniS, MarandinA, MersinN, RoyerB, KantelipB, HerveP, EtieventJP, KantelipJP. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation108: 253–258, 2003.
55.
SilvaGV, LitovskyS, AssadJA, SousaAL, MartinBJ, VelaD, CoulterSC, LinJ, OberJ, VaughnWK, BrancoRV, OliveiraEM, HeR, GengYJ, WillersonJT, PerinEC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation111: 150–156, 2005.
56.
KinnairdT, StabileE, BurnettMS, LeeCW, BarrS, FuchsS, EpsteinSE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res94: 678–685, 2004.
VanderveldeS, van LuynMJ, TioRA, HarmsenMC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol39: 363–376, 2005.
59.
HaradaM, QinY, TakanoH, MinaminoT, ZouY, TokoH, OhtsukaM, MatsuuraK, SanoM, NishiJ, IwanagaK, AkazawaH, KuniedaT, ZhuW, HasegawaH, KunisadaK, NagaiT, NakayaH, Yamauchi-TakiharaK, KomuroI. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med11: 305–311, 2005.
60.
BenaventeCA, SierraltaWD, CongetPA, MinguellJJ. Subcellular distribution and mitogenic effect of basic fibroblast growth factor in mesenchymal uncommitted stem cells. Growth Factors21: 87–94, 2003.
61.
MinguellJJ, FierroFF, EpuñanMJ, EricesAA, SierraltaWD. Nonstimulated human uncommitted mesenchymal stem cells express cell markers of mesenchymal and neural lineages. Stem Cells Dev14: 408–414, 2005.
62.
MurryCE, SoonpaaMH, ReineckeH, NakajimaH, NakajimaHO, RubartM, PasumarthiKB, ViragJI, BartelmezSH, PoppaV, BradfordG, DowellJD, WilliamsDA, FieldU. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature428: 607–608, 2004.
63.
KajsturaJ, RotaM, WhangB, CascaperaS, HosodaT, BearziC, NurzynskaD, KasaharaH, ZiasE, BonafeM, Nadal-GinardB, TorellaD, NascimbeneA, QuainiF, UrbanekK, LeriA, AnversaP. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res96: 127–137, 2005.
64.
AgbulutO, MenotML, LiZ, MarotteF, PaulinD, HagegeAA, ChomienneC, SamuelJL, MenascheP. Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy. Cardiovasc Res58: 451–459, 2003.
65.
HaiderHK, AshrafM. Bone marrow stem cell transplantation for cardiac repair. Am J Physiol Heart Circ Physiol288: H2557–H2567, 2005.
66.
GaoJ, DennisJE, MuzicRF, LundbergM, CaplanAI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs169: 12–20, 2001.
67.
LiechtyKW, MacKenzieTC, ShaabanAF, RaduA, MoseleyAM, DeansR, MarshakDR, FlakeAW. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med6: 1282–1286, 2000.
68.
BittiraB, Shum-TimD, Al-KhaldiA, ChiuRC. Mobilization and homing of bone marrow stromal cells in myocardial infarction. Eur J Cardiothorac Surg24: 393–398, 2003.
69.
BarbashIM, ChouraquiP, BaronJ, FeinbergMS, EtzionS, TessoneA, MillerL, GuettaE, ZiporiD, KedesLH, KlonerRA, LeorJ. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infracted myocardium: feasibility, cell migration, and body distribution. Circulation108: 863–868, 2003.
70.
SaitoT, KuangJQ, LinCC, ChiuRC. Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction. J Thorac Cardiovasc Surg126: 114–123, 2003.
71.
HattanN, KawaguchiH, AndoK, KuwabaraE, FujitaJ, MurataM, SuematsuM, MoriH, FukudaK. Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice. Cardiovasc Res65: 334–344, 2005.
72.
BloorCM, WhiteFC, RothDM. The pig as a model of myocardial ischemia and gradual coronary artery occlusion. In: SwindleMM, Ed. Swine as Models in Biomedical Research. Ames, IA:Iowa State University Press, pp 163–175, 1992.
73.
DickAJ, GuttmanMA, RamanVK, PetersDC, PessanhaBS, HillJM, SmithS, ScottG, McVeighER, LedermanRJ. Magnetic resonance fluoroscopy allows targeted delivery of mesenchymal stem cells to infarct borders in swine. Circulation108: 2899–2904, 2003.
74.
HillJM, DickAJ, RamanVK, ThompsonRB, YuZX, HindsKA, PessanhaBS, GuttmanMA, VarneyTR, MartinBJ, DunbarCE, McVeighER, LedermanRJ. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation108: 1009–1014, 2003.
75.
KraitchmanDL, HeldmanAW, AtalarE, AmadoLC, MartinBJ, PittengerMF, HareJM, BulteJW. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation107: 2290–2293, 2003.
76.
ShakeJG, GruberPJ, BaumgartnerWA, SenechalG, MeyersJ, RedmondJM, PittengerMF, MartinBJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg73: 1919–1925, 2002.
77.
VullietPR, GreeleyM, HalloranSM, MacDonaldKA, KittlesonMD. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet363: 783–784, 2004.
78.
KovacicJC, GrahamRM. Stem-cell therapy for myocardial diseases. Lancet363: 1735–1736, 2004.
79.
AssmusB, SchachingerV, TeupeC, BrittenM, LehmannR, DobertN, GrunwaldF, AicherA, UrbichC, MartinH, HoelzerD, DimmelerS, ZeiherAM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation106: 3009–3017, 2002.
JaquetK, KrauseKT, DenschelJ, FaesslerP, NauerzM, GeidelS, BoczorS, LangeC, StuteN, ZanderA, KuckKH. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism?Stem Cells Dev14: 299–309, 2005.
82.
StrauerBE, BrehmM, ZeusT, KosteringM, HernandezA, SorgRV, KoglerG, WernetP. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation106: 1913–1918, 2002.
83.
MenascheP, HagegeAA, VilquinJT, DesnosM, AbergelE, PouzetB, BelA, SarateanuS, ScorsinM, SchwartzK, BrunevalP, BenbunanM, MarolleauJP, DubocD. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol41: 1078–1083, 2003.
84.
PaganiFD, DerSimonianH, ZawadzkaA, WetzelK, EdgeAS, JacobyDB, DinsmoreJH, WrightS, AretzTH, EisenHJ, AaronsonKD. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans: histological analysis of cell survival and differentiation. J Am Coll Cardiol41: 879–888, 2003.
TseHF, KwongYL, ChanJK, LoG, HoCL, LauCP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet361: 47–49, 2003.
88.
AsaharaT, MasudaH, TakahashiT, KalkaC, PastoreC, SilverM, KearneM, MagnerM, IsnerJM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res85: 221–228, 1999.
89.
KawamotoA, AsaharaT, LosordoDW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med3: 221–225, 2002.
90.
TepperOM, CaplaJM, GalianoRD, CeradiniDJ, CallaghanMJ, KleinmanME, GurtnerGC. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood105: 1068–1077, 2005.
91.
YoshidaS, OnoM, ShonoT, IzumiH, IshibashiT, SuzukiH, KuwanoM. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol17: 4015–4023, 1997.
GuptaK, ZhangJ. Angiogenesis: a curse or cure?Postgrad Med J81: 236–242, 2005.
94.
YoshiokaT, AgeyamaN, ShibataH, YasuT, MisawaY, TakeuchiK, MatsuiK, YamamotoK, TeraoK, ShimadaK, IkedaU, OzawaK, HanazonoY. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. Stem Cells23: 355–364, 2005.
95.
ChenSL, FangWW, YeF, LiuYH, QianJ, ShanSJ, ZhangJJ, ChunhuaRZ, LiaoLM, LinS, SunJP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol94: 92–95, 2004.
96.
FlorenzanoF, MinguellJJ. Autologous mesenchymal stem cell transplantation after acute myocardial infarction. Am J Cardiol95: 435, 2005.
97.
Tateishi-YuyamaE, MatsubaraH, MuroharaT, IkedaU, ShintaniS, MasakiH, AmanoK, KishimotoY, YoshimotoK, AkashiH, ShimadaK, IwasakaT, ImaizumiT. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet360: 427–435, 2002.
98.
HaynesworthSE, BaberMA, CaplanAI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol166: 585–592, 1996.
99.
EricesA, CongetP, RojasC, MinguellJJ. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res280: 24–32, 2002.
100.
TangYL, ZhaoQ, QinX, ShenL, ChengL, GeJ, PhillipsMI. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg80: 229–236, 2005.
101.
PakHN, QayyumM, KimDT, HamabeA, MiyauchiY, LillMC, FrantzenM, TakizawaK, ChenLS, FishbeinMC, SharifiBG, ChenPS, MakkarR. Mesenchymal stem cell injection induces cardiac nerve sprouting and increased tenascin expression in a swine model of myocardial infarction. J Cardiovasc Electrophysiol14: 841–848, 2003.
102.
CampagnoliC, RobertsIA, KumarS, BennettPR, BellantuonoI, FiskNM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood98: 2396–2402, 2001.
103.
RomanovYA, SvintsitskayaVA, SmirnovVN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells21: 105–110, 2003.
104.
IguraK, ZhangX, TakahashiK, MitsuruA, YamaguchiS, TakashiTA. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy6: 543–553, 2004.
105.
HannIM, BodgerMP, HoffbrandAV. Development of pluripotent hematopoietic progenitor cells in the human fetus. Blood62: 118–123, 1983.
106.
TavassoliM. Embryonic and fetal hemopoiesis: an overview. Blood Cells17: 269–281, 1991.
107.
BianchiDW, ZickwolfGK, WeilGJ, SylvesterS, DeMariaMA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A93: 705–708, 1996.
108.
O'donoghueK, ChoolaniM, ChanJ, de la FuenteJ, KumarS, CampagnoliC, BennettPR, RobertsIA, FiskNM. Identification of fetal mesenchymal stem cells in maternal blood: implications for noninvasive prenatal diagnosis. Mol Hum Reprod9: 497–502, 2003.
109.
DennisJE, CharbordP. Origin and differentiation of human and murine stroma. Stem Cells20: 205–214, 2002.
110.
OberlinE, TavianM, BlazsekI, PeaultB. Blood-forming potential of vascular endothelium in the human embryo. Development129: 4147–4157, 2002.
111.
PeaultB, TavianM. Hematopoietic stem cell emergence in the human embryo and fetus. Ann N Y Acad Sci996: 132–140, 2003.
112.
NiedaM, NicolA, Denning-KendallP, SweetenhamJ, BradleyB, HowsJ. Endothelial cell precursors are normal components of human umbilical cord blood. Br J Haematol98: 775–777, 1997.
113.
MayaniH, Gutierrez-RodriguezM, EspinozaL, Lopez-ChaliniE, Huerta-ZepedaA, FloresE, Sanchez-ValleE, Luna-BautistaF, ValenciaI, RamirezOT. Kinetics of hematopoiesis in Dexter-type long-term cultures established from human umbilical cord blood cells. Stem Cells16: 127–135, 1998.
114.
in'tAnkerPS, NoortWA, ScherjonSA, Kleijburg-van der KeurC, KruisselbrinkAB, van BezooijenRL, BeekhuizenW, WillemzeR, KanhaiHH, FibbeWE. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica88: 845–852, 2003.
115.
BiebackK, KernS, KluterH, EichlerH. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells22: 625–634, 2004.
KoglerG, SenskenS, AireyJA, TrappT, MuschenM, FeldhahnN, LiedtkeS, SorgRV, FischerJ, RosenbaumC, GreschatS, KnipperA, BenderJ, DegistiriciO, GaoJ, CaplanAI, CollettiEJ, Almeida-PoradaG, MullerHW, ZanjaniE, WernetP. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med200: 123–135, 2004.
118.
Le BlancK, TammikC, RosendahlK, ZetterbergE, RingdenO. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol31: 890–896, 2003.
119.
GotherstromC, RingdenO, WestgrenM, TammikC, Le BlancK. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant32: 265–272, 2003.
120.
GotherstromC, RingdenO, TammikC, ZetterbergE, WestgrenM, Le BlancK. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol190: 239–245, 2004.
KocON, GersonSL, CooperBW, DyhouseSM, HaynesworthSE, CaplanAI, LazarusHM. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol18: 307–316, 2000.
123.
Le BlancK, RasmussonI, GotherstromC, SeidelC, SundbergB, SundinM, RosendahlK, TammikC, RingdenO. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol60: 307–315, 2004.
124.
Le BlancK, GotherstromC, RingdenO, HassanM, McMahonR, HorwitzE, AnnerenG, AxelssonO, NunnJ, EwaldU, Norden-LindebergS, JanssonM, DaltonA, AstromE, WestgrenM. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation79: 1607–1614, 2005.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS, GianniAM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood99: 3838–3843, 2002.
127.
Le BlancK, TammikL, SundbergB, HaynesworthSE, RingdenO. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol57: 11–20, 2003.
128.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE, DazziF. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood101: 3722–3729, 2003.
129.
MaitraB, SzekelyE, GjiniK, LaughlinMJ, DennisJ, HaynesworthSE, KocON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant33: 597–604, 2004.
130.
Le BlancK, RasmussonI, SundbergB, GotherstromC, HassanM, UzunelM, RingdenO. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet363: 1439–1441, 2004.
131.
MeiselR, ZibertA, LaryeaM, GobelU, DaubenerW, DillooD. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood103: 4619–4621, 2004.
132.
AugelloA, TassoR, NegriniSM, AmateisA, IndiveriF, CanceddaR, PennesiG. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol35: 1482–1490, 2005.
133.
JiangXX, ZhangY, LiuB, ZhangSX, WuY, YuXD, MaoN. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood105: 4120–4126, 2005.
134.
BeythS, BorovskyZ, MevorachD, LiebergallM, GazitZ, AslanH, GalunE, RachmilewitzJ. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood105: 2214–2219, 2005.
MaccarioR, PodestaM, MorettaA, CometaA, ComoliP, MontagnaD, DaudtL, IbaticiA, PiaggioG, PozziS, FrassoniF, LocatelliF. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica90: 516–525, 2005.
137.
RasmussonI, RingdenO, SundbergB, Le BlancK. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation76: 1208–1213, 2003.
TseWT, PendletonJD, BeyerWM, EgalkaMC, GuinanEC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation75: 389–397, 2003.
141.
Barda-SaadM, RozenszajnLA, AshushH, Shav-TalY, Ben NunA, ZiporiD. Adhesion molecules involved in the interactions between early T cells and mesenchymal bone marrow stromal cells. Exp Hematol27: 834–844, 1999.
142.
MajumdarMK, ThiedeMA, MoscaJD, MoormanM, GersonSL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol176: 57–66, 1998.
143.
GersonSL. Mesenchymal stem cells: no longer second class marrow citizens. Nat Med5: 262–264, 1999.
